Consequently, combination of MEKi trametinib and AXL inhibitor R428 synergistically reduced tumour growth and metastasis in orthotopic TNBC (and melanoma) xenograft models derived from cell lines that showed increased surface AXL following MEKi. The gene discussed is AXL; the disease is neoplasm.